Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

9820	Companies
197077	Keywords
128165	Articles
104819	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 10/06/2025 at 15:00, 4 months ago

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals provides update on ongoing clinical trial for the treatment of MVID in pediatric patients, showing significant reduction in parenteral support in UAE. FDA advice sought for study advancement

FDA Napo Pharmaceuticals Clinical Trial Pediatric Patients MVID
BRIEF

published on 09/30/2025 at 15:05, 4 months 6 days ago

Jaguar Health Provides Crofelemer for Pediatric Intestinal Failure Treatment

Crofelemer Microvillus Inclusion Disease Jaguar Health Pediatric Treatment FDA Programs
BRIEF

published on 09/30/2025 at 15:05, 4 months 6 days ago

Jaguar Health fournit Crofelemer pour le traitement de l'insuffisance intestinale pédiatrique

Crofelemer Jaguar Health Maladie D'inclusion Microvillositaire Traitement Pédiatrique Programmes De La FDA
PRESS RELEASE

published on 09/30/2025 at 15:00, 4 months 6 days ago

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease
Jaguar Health announces expanded access programs for pediatric patients with microvillus inclusion disease using crofelemer powder. Positive results from initial trials presented

Microvillus Inclusion Disease Jaguar Health Pediatric Patients Crofelemer Powder Expanded Access Programs
BRIEF

published on 09/26/2025 at 12:22, 4 months 10 days ago

Jaguar Health Inc. réitère sa recommandation d'achat sur ses actions

Financement Jaguar Health Maladies Rares Premier Berlin Recommandation D'actions
BRIEF

published on 09/26/2025 at 12:22, 4 months 10 days ago

Jaguar Health Inc's Stock Recommendation Reiterated as BUY

Funding Jaguar Health Stock Recommendation Rare Diseases First Berlin
PRESS RELEASE

published on 09/26/2025 at 12:17, 4 months 10 days ago

Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates recommendation for Jaguar Health Inc to BUY with a target price of USD 35. Company reports H1/25 results in line with estimates, focuses on securing funding for promising pipeline

Jaguar Health Inc Funding First Berlin Equity Research Buy Recommendation Research Update
BRIEF

published on 09/25/2025 at 15:05, 4 months 11 days ago

Jaguar Health obtient une subvention de 250 000 $ de la FDA pour l'essai Canalevia

Jaguar Health Santé Animale Canalevia Traitement De La Diarrhée Canine Subvention De La FDA
BRIEF

published on 09/25/2025 at 15:05, 4 months 11 days ago

Jaguar Health Secures $250,000 FDA Grant for Canalevia Trial

Jaguar Health Animal Health Canalevia Dog Diarrhea Treatment FDA Grant
PRESS RELEASE

published on 09/25/2025 at 15:00, 4 months 11 days ago

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Animal Health receives $250,000 grant from FDA's CVM for Canalevia-CA1 to treat chemotherapy-induced diarrhea in dogs. Company seeks to expand partnership for global commercialization of Canalevia

Canalevia-CA1 Chemotherapy-induced Diarrhea Jaguar Animal Health Global Commercialization FDA Grant

Accesswire

Published on 02/07/2026 at 01:00, 11 hours 11 minutes ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 13 hours 1 minute ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 14 hours 10 minutes ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 20 hours 41 minutes ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 22 hours 41 minutes ago

Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange

View all ACCESSWIRE

EQS Group

Published on 02/06/2026 at 19:25, 16 hours 45 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 18 hours 19 minutes ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 17:40, 18 hours 31 minutes ago

Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.01.26.
Published on 02/06/2026 at 16:55, 19 hours 16 minutes ago

GAC MPV Serves as Official Reception Fleet for APEC China 2026, Demonstrating the Strength of Chinese Manufacturing
Published on 02/06/2026 at 15:25, 20 hours 46 minutes ago

CES 2026 Innovation Award Honoree iGarden M1 Pro Max Launches as World's First Bionic Dual-Vision Pool Cleaner

Les Echos

Published on 02/06/2026 at 18:22, 17 hours 49 minutes ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 17 hours 49 minutes ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 20 hours 10 minutes ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 20 hours 10 minutes ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 1 day 4 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE